Tobacco use, particularly cigarette smoking, is now a global pandemic. The expected
morbidity and mortality from smoking-attributable diseases will continue to rise for the next …

Cigarette smoking represents one of the most preventable causes of death worldwide.
However, success rates for stopping smoking are disappointingly low and are associated …

The advent of bupropion hydrochloride sustained release (Zyban) has heralded a major
change in the options available for smoking cessation pharmacotherapy. Bupropion is a …

Bupropion SR was introduced for smoking cessation in the US in 1997. This review
assesses the efficacy and safety of bupropion SR for treatment of tobacco dependence …

Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an
aid to smoking cessation. In 2 large well designed clinical trials, sustained release …

Background: Knowledge pertaining to the effectiveness of smoking cessation treatments and
patient characteristics that may affect success may enable smokers and clinicians to select …

Cigarette dependence is recognised as a life-threatening disorder which can be treated by
behavioural support and/or medication. Bupropion hydrochloride sustained-release …

Nicotine addiction is a chronic relapsing condition that can be difficult to treat. Until recently,
pharmacological options for the treatment of tobacco dependence were primarily limited to …

Smoking tobacco is the leading cause of preventable death. Bupropion is the only
antidepressant recommended as first-line pharmacotherapy for smoking cessation …

Bupropion hydrochloride, an atypical antidepressant, is the first non‐nicotine product that, in
its sustained release form (bupropion SR), has been licensed as an aid for smoking …